Johns Hopkins

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Retrieved on: 
Donnerstag, Mai 9, 2024
Johns Hopkins University, Traumatic brain injury, MSN, Danaher Corporation, BSN, Risk, DHR, Blood, Johns Hopkins, MD, Doctor of Philosophy, Research, TBI, Brain damage, Beacon, Patient, RN, Diagnosis, Brain, Biomarker, Emergency medicine, Medical imaging

This approach could potentially be adapted for diagnosis of other neurological conditions.

Key Points: 
  • This approach could potentially be adapted for diagnosis of other neurological conditions.
  • WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI.
  • As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
  • The Danaher Beacon for Brain Injury Diagnostics is the sixth collaboration in the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)

Retrieved on: 
Montag, Mai 6, 2024
Safety, CST, Johns Hopkins, Partnership, Computational biology, DRS, Patient, Peptide, Therapy, Retina, Pharmaceutical industry

Fifteen patients have completed enrollment in the trial for AXT107 (gersizangitide).

Key Points: 
  • Fifteen patients have completed enrollment in the trial for AXT107 (gersizangitide).
  • Secondary endpoints will include efficacy as assessed by central subfield thickness (CST) and best-corrected visual acuity (BCVA).
  • “I would like to thank the team and sites for their unwavering commitment, collaborative spirit, and meticulous execution they brought to the enrollment of the DISCOVER trial,” said Robert J. Dempsey, Chief Executive Officer, AsclepiX Therapeutics.
  • “Rapid enrollment was a tribute to the partnership of our principal investigators Drs.

Southeastern Grocers donates $320,000 to 8 children’s hospitals and celebrates Mother’s Day

Retrieved on: 
Donnerstag, Mai 9, 2024
Teens, Other Consumer, Parenting, Women, Children, Other Philanthropy, Seniors, Baby, Maternity, Health, Religion, Professional Services, Men, Philanthropy, Family, Consumer, LGBTQ+, Fund Raising, Foundation, Supply Chain Management, Supermarket, Online Retail, Food, Beverage, Social Services, Hospitals, Retail, Snack, Golisano, Harveys Supermarkets, Hospital, Winn-Dixie, Johns Hopkins, Happiness, Research, Patient, Child, Multimedia, Mother, Meat, Grocery store

Southeastern Grocers Inc. (SEG), parent company and home of Harveys Supermarket and Winn-Dixie grocery stores, donated $320,000 to eight children’s hospitals across the Southeast to aid the health and healing of local pediatric patients.

Key Points: 
  • Southeastern Grocers Inc. (SEG), parent company and home of Harveys Supermarket and Winn-Dixie grocery stores, donated $320,000 to eight children’s hospitals across the Southeast to aid the health and healing of local pediatric patients.
  • View the full release here: https://www.businesswire.com/news/home/20240509824934/en/
    Southeastern Grocers Inc. (SEG), parent company and home of Harveys Supermarket and Winn-Dixie grocery stores, donates $320,000 to eight children’s hospitals across the Southeast.
  • The grocer is also surprising moms caring for hospitalized children leading up to Mother’s Day with gift cards, fresh flowers and breakfast treats, including families at Golisano Children’s Hospital of Southwest Florida.
  • Raymond Rhee, Chief People Officer for Southeastern Grocers, said, “These eight exceptional children's hospitals hold a special place within our communities, similar to the vital role mothers play within their families.

Vizient/AACN Nurse Residency Program announces integration of Maryland R3 curriculum

Retrieved on: 
Montag, Mai 6, 2024
Nursing, Medical Supplies, Practice Management, Education, Managed Care, Health, General Health, Pharmaceutical, Medical Devices, Hospitals, Other Education, NRP, School, Safety, Johns Hopkins, Curriculum, Culture, Workforce, AACN

The Vizient/American Association of College Nursing (AACN) Nurse Residency Program™ announced today the integration of Maryland’s R3 Resilient Nurses Initiative curriculum into its content offering.

Key Points: 
  • The Vizient/American Association of College Nursing (AACN) Nurse Residency Program™ announced today the integration of Maryland’s R3 Resilient Nurses Initiative curriculum into its content offering.
  • Rushton is the co-creator of the Mindful Ethical Practice and Resilience Academy (MEPRA) and the Rushton Moral Resilience Scale.
  • “The Vizient/AACN Nurse Residency Program is committed to driving excellence in nursing practice,” said Evy Olson, vice president of Nursing Programs at Vizient.
  • “Integrating the R3 tools into the NRP curriculum reflects our dedication to providing nurses with the tools for long, healthy careers in nursing.”

Greenboard Announces $4.5M Seed Round from Base10 Partners to be "Rippling for financial compliance and operations"

Retrieved on: 
Mittwoch, Mai 8, 2024
Hive, System, Partner, Risk, Johns Hopkins, Software, Computer, Partnership, Cloud computing, Amazon, Human, KYE, Y Combinator, Guideline, Decimal, Philosophy, Cryptocurrency

"We founded Greenboard after witnessing how cumbersome and outdated compliance software is at most financial firms," said Dave Feldman, Co-founder and CEO of Greenboard.

Key Points: 
  • "We founded Greenboard after witnessing how cumbersome and outdated compliance software is at most financial firms," said Dave Feldman, Co-founder and CEO of Greenboard.
  • "This fundraise, along with our partnership with Base10, will help us enable financial institutions to operate their back office teams at a higher standard, with half of the headcount.
  • Greenboard's core product thesis is that GPU-powered computational statistics will eliminate much of the tedium in back office financial work.
  • "Greenboard's innovative approach to financial compliance and operations aligns perfectly with our investment philosophy at Base10," said Rexhi Dollaku, Partner at Base10 Partners.

Santa J. Ono, University of Michigan President, Joins USJF Board

Retrieved on: 
Dienstag, Mai 7, 2024
Education, American Academy, University, Harvard University, Fulbright Program, USJF, United, Competition (economics), University College London, Teaching, The arts, Johns Hopkins, Research, Parent, Friends, Council, Family, Institute for Advanced Study, Mental health, Microbiology, Society, Macular degeneration, Creativity, Ophthalmology, Organization, Knowledge, Nursing

WASHINGTON, May 7, 2024 /PRNewswire/ -- Santa J. Ono, president of the University of Michigan, has joined the United States-Japan Foundation Board of Trustees.

Key Points: 
  • WASHINGTON, May 7, 2024 /PRNewswire/ -- Santa J. Ono, president of the University of Michigan, has joined the United States-Japan Foundation Board of Trustees.
  • Ono has received an honorary doctorate from Chiba University and was also elected to the American Academy of Arts & Sciences.
  • "We are thrilled to be able to add somebody with Santa Ono's demonstrated leadership, and deep ties to Japan, to our board," said Lawrence K. Fish, USJF board chair.
  • Before moving to Ann Arbor as Michigan's 15th president in October 2022, Ono was president of the University of British Columbia, and the University of Cincinnati.

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Retrieved on: 
Donnerstag, Mai 2, 2024
University, Cancer, Johns Hopkins Hospital, IND, Genetics, Johns Hopkins, Pancreas, Thomas Jefferson University, Patient, Macrophage, CARM, Louisiana State University, Associate, Therapy, Lumos, Medical college

PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of clinical and industry experience, including cross-functional leadership driving clinical development and regulatory strategies for oncology and immuno-oncology focused organizations. In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions.

Key Points: 
  • In the role of Chief Medical Officer, Dr. Kennedy will be responsible for overseeing Carisma's clinical development, regulatory and medical affairs functions.
  • "On behalf of Carisma, I am delighted to welcome Gene to our team," said Steven Kelly, President and Chief Executive Officer of Carisma.
  • Before joining Carisma, Dr. Kennedy served as Chief Medical Officer at Galera Therapeutics, where he oversaw the development of the company's radiotherapy in cancer.
  • Before Lumos, Dr. Kennedy held the role of Chief Medical Officer at NewLink Genetics, overseeing clinical trials across multiple product candidates and indications.

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Retrieved on: 
Mittwoch, April 24, 2024
Cancer, MSS, Poster, Colorectal cancer, Johns Hopkins, CRC, MSI-L, ICI, ASCO, Society, Assistant, Annual general meeting, Ovarian cancer

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.

Key Points: 
  • BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.
  • Title: A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer

Bayh-Dole Coalition Launches Campaign Against Proposed March-in Framework

Retrieved on: 
Dienstag, April 30, 2024
School, Johns Hopkins, HIV, Yale University, Duke, Invention, University, Language, Bayh–Dole Act, Research

The campaign will educate Americans on the dangers of the proposal and help them mobilize against it. Sixteen of the nation's leading technology transfer officials explain how the proposal will undermine scientists and engineers at universities nationwide -- and deter startups from licensing those schools' early-stage research discoveries and working to turn them into real-world products.

Key Points: 
  • The proposed changes would jeopardize cutting-edge research and prevent the creation of life-changing technologies.
  • The campaign will educate Americans on the dangers of the proposal and help them mobilize against it.
  • "By twisting the language of the Bayh-Dole Act, the proposed framework threatens the very foundations of our country's innovation system."
  • The SaveBayhDole.org site also makes it easy for concerned citizens to contact their congressional representatives and urge them to oppose the framework.
    "

Aster Insights announces Johns Hopkins All Children's Hospital joins the Oncology Research Information Exchange Network (ORIEN)

Retrieved on: 
Dienstag, April 30, 2024
Patient, Cancer, Hospital, Health, Johns Hopkins, Estate (law), Collection, Research, History, TCC, Biomarker, Clinical trial, Knowledge, Pharmaceutical industry

TAMPA and ST. PETERSBURG, Fla., April 30, 2024 /PRNewswire/ -- Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, announced today that Johns Hopkins All Children's Hospital will join its Oncology Research Information Exchange Network® (ORIEN) as the newest member of the consortium. By joining ORIEN®, children with cancer receiving care at Johns Hopkins All Children's Hospital will be able to participate in this research to identify novel oncology cures. With this addition, ORIEN® will be comprised of 19 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer medical product discovery and development.

Key Points: 
  • TAMPA and ST. PETERSBURG, Fla., April 30, 2024 /PRNewswire/ -- Aster Insights , the leading provider of scientific and clinical intelligence for oncology discovery, announced today that Johns Hopkins All Children's Hospital will join its Oncology Research Information Exchange Network® ( ORIEN ) as the newest member of the consortium.
  • By joining ORIEN®, children with cancer receiving care at Johns Hopkins All Children's Hospital will be able to participate in this research to identify novel oncology cures.
  • "The addition of Johns Hopkins All Children's Hospital to ORIEN is a major milestone in the history of ORIEN and Aster Insights," said Dr. Erin Siegel, ORIEN® Steering Committee Chair.
  • Aster Insights leads the Total Cancer Care study and oversees ongoing data and specimen collection from patients across ORIEN®.